Background

Dengue, one of the most common arboviral infections, is transmitted by the bite of the Aedes mosquito. Dengue infections are caused by four circulating dengue virus serotypes (DENV-1 to -4) that are ubiquitously prevalent throughout the tropical and subtropical regions of the world. The risk of infection is strongly influenced by rainfall, temperature and the degree of urbanization [1, 2]. Dengue infection is usually asymptomatic in > 50% of cases; alternatively, it can present as a flu-like illness, including headache, myalgia and rash [3]. Therefore, knowledge of dengue's geographical distribution and burden is crucial [2]. To date, there are not licensed vaccines or specific therapeutics against dengue [2].

Dengue is one of the major public health concerns in developing countries. More than 100 countries in South East Asia, the Western Pacific region, the Americas and Africa are reported to be dengue endemic, a scenario that differs from that which prevailed 20–30 years ago [3]. Dengue is considered to be among the most significant infectious diseases, having a high disease burden, especially in the South East Asia region, with cycles of epidemics every 3–5 years [4]. Bhatt et al. estimated 390 million dengue infections worldwide in 2010, much higher than the number of cases previously assumed by WHO [2]. Shepherd et al. estimated an average of 2.9 million dengue infection episodes and 5906 deaths per year with an annual economic burden of US$950 million in the Southeast Asian region [5].

Similarly, the disability-adjusted life years (DALYS) of dengue in the South East Asian region was 372 DALYs per million per year [5]. This trend is projected to rise further in the future owing to the rapid population growth in the region together with unplanned urbanization and industrialization, increased population sensitivity and lack of licensed vaccines and specific therapeutics against dengue [2, 4]. Although all eight countries in the South Asian Association for Regional Cooperation (SAARC) region reported sporadic cases or outbreaks of dengue infection with significant health and economic burden, no has yet study scrutinized its prevalence and risk factors among the febrile and healthy general population in the SAARC region to date. The aim of our meta-analysis was, therefore, to evaluate the prevalence, risk factors and distribution of dengue fever in SAARC countries.

Methods

Protocol registration

The systematic review was registered in PROSPERO (CRD42020215737) and was conducted according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines [6, 7]. For details, see Additional file 1: Text 1.

Data sources and search strategy

The PubMed, PubMed Central, Scopus and Embase databases were searched for relevant articles from 1995 up to December 2020 using the appropriate terms and Boolean operators. For details, see Additional file 2: Text 1.

Eligibility and exclusion criteria

The eligibility criteria for inclusion were: (i) all papers (cross-sectional studies, case series reporting > 50 patients with dengue, cohort study) mentioning prevalence of dengue and/or details of dengue-like risk factors, outcome and outcome predictors; (ii) studies conducted between 1995 onwards to date; (iii) published articles. The following studies were excluded: (i) editorials, comments, and viewpoint articles with no proper data on dengue and lacking adequate data of interest; and (ii) studies conducted outside SAARC countries. When ≥ 2 studies were identified that used the same dataset, we considered the most comprehensive and updated one for inclusion.

Study selection

The studies were filtered using Covidence [8]. Three reviewers (BG, SS, AB) independently screened the title and abstract based on the inclusion criteria. Discrepancies were resolved by consensus, with a fourth reviewer (SA) making the decision when consensus could not be reached.

Risk of bias assessment based on the critical appraisal checklist

Qualitative assessment of each individual study was conducted using the Joanna Briggs Institute (JBI) critical appraisal tool [9]. This checklist consists of nine items that assess the methodological quality of an investigation and determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis. Our bias assessment of the 55 articles included in our meta-analysis is shown in Table 1.

Table 1 Bias assessment of the studies included in the meta-analysis

Subgroup analysis

Subgroup analyses were conducted based on countries.

Results

Our thorough search of the databases resulted in the identification of 24,354 studies. Following removal of all duplicate studies, we screened the, titles and abstracts of 15,773 studies, resulting in the exclusion of 14,980 studies; the eligibility of the remaining 773 studies was assessed on the basis of the full text. Ultimately, 55 studies were included in the final quantitative analysis (Fig. 1). The narrative summary is presented in Table 2.

Fig. 1
figure 1

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of study selection process

Table 2 Narrative summary of included studies

Confirmed dengue-positive cases

A total of 37 studies reported confirmed dengue cases among suspected cases of dengue (Fig. 2). Pooling of the data using a random-effects model showed that 30.7% (proportion: 0.307, 95% CI: 0.277–0.339, I2: 99.42%) of the suspected cases were confirmed to be dengue. The proportion of confirmed cases varied from country to country in the SAARC countries. In Bhutan, one study reported that the proportion of confirmed dengue cases was 31.4%. In India, 25 studies reported confirmed dengue cases among suspected cases, with the proportion of confirmed cases ranging from 11% to 74.5% across the studies; the pooled proportion of confirmed cases across all studies was 32.5% (progression: 0.325, 95% CI: 0.275–0.378). In Nepal, six studies reported confirmed dengue cases among the suspected cases, with the proportion ranging from 9.9% to 33.2% across different studies; the pooled proportion of confirmed cases was 20% (proportion: 0.200, 95% CI: 0.135–0.287). Five studies from Pakistan reported the proportion of confirmed cases among suspected dengue cases, with a range of 20.5% to 52.1%; the pooled proportion of confirmed cases across all studied was 32.7% (proportion: 0.327, 95% CI: 0.223–0.458) (Fig. 2).

Fig. 2
figure 2

Forest plot showing the proportion of dengue cases across different countries among suspected cases of dengue using a random-effect model. Abbreviation: CI confidence, interval

Dengue immunoglobulin M seroprevalence

A total of 31 studies reportedly the seroprevalence of dengue immunoglobulin M (IgM) antibodies (Fig. 3). Pooling the data using a random effect model across all the studies showed a seroprevalence of 34.2% (proportion: 0.342, 95% CI: 0.318–0.366, I2: 99.26%). One study from Bhutan showed a seroprevalence of 7.7%, and 21 studies from India reported seroprevalence ranging from 2.6% to 61.6%, with a pooled dengue IgM seroprevalence of 23.3% (proportion: 0.233, 95% CI: 0.182–0.293). Five studies reported seroprevalence from Nepal, ranging from 9.9% to 29.3%, with a pooled dengue IgM seroprevalence 17.8% (proportion: 0.178, 95% CI: 0.123–0.251). Three studies reported dengue IgM seroprevalence from Pakistan, with a pooled prevalence of 35.2% (proportion: 0.352, 95% CI: 0.321–0.383). Finally, one study from Sri Lanka showed a dengue IgM seroprevalence of 76.6% (Fig. 3).

Fig. 3
figure 3

Forest plot showing the proportion of seroprevalence of dengue immunoglobulin M (IgM) antibodies across different countries among suspected cases of dengue using a random-effect model

Dengue NS1 seroprevalence

Twelve studies reported the seroprevalence of NS1 antigen, and pooling of these results showed dengue NS1 positivity in 24.1% of the cases (proportion: 0.241, 95% CI: 0.205–0.282, I2: 99.4) (Fig. 4).

Fig. 4
figure 4

Forest plot showing the proportion of dengue IgM seroprevalence across different countries among suspected cases of dengue using a random-effect model

Dengue immunoglobulin G seroprevalence

Nine studies reported the seroprevalence of dengue immunoglobulin G (IgG) antibodies (Fig. 5). Pooling of the data showed dengue IgG positivity in 34.6% of cases (proportion: 0.346, 95% CI: 0.311–0.382, I2: 99.67) (Fig. 5).

Fig. 5
figure 5

Forest plot showing the proportion of dengue immunoglobulin G (IgG) seroprevalence across different countries among suspected cases of dengue using a random-effect model

Combined dengue IgM and IgG seroprevalence

Ten studies reported seroprevalence of both IgM and IgG antibodies of dengue (Fig. 6). Pooling of these results showed positivity for both dengue IgM and IgG antibodies in 29.0% of cases (proportion: 0.290, 95% CI: 0.249–0.334, I2: 99.02) (Fig. 6).

Fig. 6
figure 6

Forest plot showing the proportion of both IgM and IgG seroprevalence of dengue across different countries among suspected cases of dengue using a random-effect model

DENV virus strain

A total of 16 studies reported on the different strains of DENV, with the proportion of different strains varying between studies (Figs. 7, 8). A study from Bhutan reported that DENV-1 was the most prevalent strain in that country (91.4%). Studies from Sri Lanka, India and Nepal reported differences in the prevalence of specific strains among these three countries, with the predominant DENV strain(s) being DNV-1 and DNV-2 in Nepal, DNV-2 and DNV-3 in Sri Lanka and DNV-4 in Sri Lanka. In contrast, in India, all four strains were reported to be circulating in different parts of the country, with, overall, DENV-1 accounting for 21.8% (proportion: 0.18, 95% CI: 0.128–0.346), DENV-2 accounting for 41.2% (proportion: 0.412, 95% CI: 0.250–0.583), DENV-3 accounting for 14.7% (proportion: 0.137, 95% CI: 0.091–0.201) and DENV-4 accounting for 6.3% (proportion: 0.063, 95% CI: 0.023–0.119) (Figs. 7, 8).

Fig. 7
figure 7

Forest plot showing the proportion of dengue virus strains 1 and 2 (DENV-1, DENV-2) across different countries among confirmed cases of dengue using a random-effect model

Fig. 8
figure 8

Forest plot showing the proportion of DENV-3 and DENV-4 across different countries among confirmed cases of dengue using a random-effect model

Residential setting (urban versus rural)

Thirteen studies reported the residential setting of patients with dengue (Fig. 9). Pooling of these data showed the 46.95% of dengue cases were from rural settings (proportion: 0.469, 95% CI: 0.369–0.571) and that 53.1% were from urban residential settings (proportion 0.531, 95% CI: 0.429–0.631) (Fig. 9).

Fig. 9
figure 9

Forest plot showing the proportion of dengue cases based on residential setting across different countries among cases of dengue using a random-effect model

Dengue severity

Dengue fever

Sixteen studies reported dengue fever (Fig. 10). Pooling the data using the random effects model showed that 80.5% of the cases were categorized as dengue fever (proportion: 0.805, 95% CI: 0.765–0.839, I2: 98.86) (Fig. 10).

Fig. 10
figure 10

Forest plot showing the proportion of dengue fever cases across different countries among cases of dengue using a random-effects model

Dengue hemorrhagic fever

Sixteen studies reported dengue hemorrhagic fever (DHF) (Fig. 11). Pooling of the data using the random-effects model showed that 18.2% of the cases were categorized as DHF (proportion: 0.182,, 95% CI: 0.150–0.220, I2: 98.73) (Fig. 11).

Fig. 11
figure 11

Forest plot showing the proportion of dengue hemorrhagic fever cases across different countries among cases of dengue using a random-effects model

Dengue shock syndrome

Sixteen studies reported dengue shock syndrome (Fig. 12). Pooling of the data using a random-effects model showed that 1.5% of the cases were categorized as dengue shock syndrome (proportion: 0.015, 95% CI: 0.010–0.024, I2: 96.70) (Fig. 12).

Fig. 12
figure 12

Forest plot showing the proportion of dengue shock syndrome cases across different countries among cases of dengue using a random-effects model

Fever as a symptom

A total of 34 studies reported the status of fever as a symptom (Fig. 13). Pooling the data using the random-effects model showed that 98.7% of the patients had a fever, which was the most typical symptom reported (proportion: 0.987, 95% CI: 0.978–0.992, I2: 95.06) (Fig. 13).

Fig. 13
figure 13

Forest plot showing the proportion of fever among cases of dengue across different countries using a random-effects model

Thrombocytopenia

A total of 25 studies reported thrombocytopenia among dengue cases (Fig. 14). Pooling these findings using the random-effects model showed that 44.7% of patients had a low platelet count (proportion: 0.447, 95% CI: 0.399–0.496, I2: 98.77) (Fig. 14).

Fig. 14
figure 14

Forest plot showing the proportion of thrombocytopenia among cases of dengue across different countries using a random-effects model

Mortality outcome

Mortality was reported in 25 studies (Fig. 15). Pooling these data using a random-effects model showed that mortality was reported in 1.9% of dengue cases (proportion: 0.019, 95% CI: 0.014–0.027, I2: 97.4) (Fig. 15).

Fig. 15
figure 15

Forest plot showing mortality among cases of dengue across different countries using a random-effects model

Publication bias

Publication bias is among the different outcomes assessed using the Funnel plot and Egger’s test. Rough estimates for publication bias were based on the symmetry of the Funnel plot and confirmed using the Egger’s test. Publication bias was significant for the confirmed dengue-positive cases and the ‘fever as a symptom’ outcome (P < 0.05); for the remaining other outcomes, publication bias was not significant (P > 0.05).

Discussion

The present study reports on the epidemiology of dengue infection in SAARC countries over the past 2.5 decades. There was a substantial discrepancy in the proportion of laboratory-confirmed dengue infections among the SAARC countries, with the highest proportion reported in Pakistan and the lowest reported in Nepal. The overall pooled proportion of confirmed cases among suspected cases was 30.7%, with a significantly increased heterogeneity that varies according to country and time frame of the studies, infection marker of interest, severity and outcome [65]. This prevalence is very high compared to the pooled proportion of autochthonous dengue infections in Europe (0.7%). In a systematic review study by Ganeshkumar et al. in 2018, the pooled proportion of dengue infections in India was 38.3% [66]. We were unable to determine the proportion of dengue infections in a number of SAARC countries, including Afghanistan, Bangladesh, Maldives and Sri Lanka, due to the lack of published studied from these countries.

In this study, the pooled seroprevalence of dengue infection based on markers, namely IgM and IgG antibodies and NS1 antigen was 34.2, 35.2 and 24.1%, respectively. In comparison, the pooled seroprevalence of dengue infection based on both IgM and IgG seropositivity was 29.0%. These values are similar to those reported by Li et al., who found that the worldwide seroprevalence of dengue infection was 38%, with the highest dengue seroprevalence, namely 56%, in the South East Asia region and the lowest, namely 4%, in the European arena [67]. However, IgM, IgG and DENV-RNA pooled seroprevalence in febrile participants of Africa was reported to be 8.4, 10.8 and 24.8%, respectively [68]. Similarly, the seroprevalence in the general population of the Middle East and North Africa was reported by Humphrey et al. to be 25% (range: 0–62%) from 1941 to 2015 [69].

The likely explanation for the increased clinical and serological prevalence of dengue cases in SAARC countries could be the climate, geographic distribution of mosquito vectors, urbanization and absence or failure of appropriate vector control measures [70,71,72,73]. Based on a thermodynamic model, dengue virus transmission increases at a mean temperature of < 18 °C as the diurnal temperature range increases, indicating that small fluctuations in temperature favor dengue virus development [74, 75].

Our study showed that different strains of the dengue virus were predominant in different countries of SAARC. DENV-2 was most predominant dengue virus strain (41.2%), followed by DENV-1 (21.8%). The DENV-2 strain is considered to be the most virulent and life-threatening of the four serotypes [76]. The predominance of different DENV strains in different areas could be due to selection during DENV evolution, as well as viral fitness in the human or mosquito host that allows some lineages to survive better than others [77]. Therefore, the dynamics of serotype oscillations is a complex phenomenon. In our study, DENV-2 and DENV-3 were predominant in Sri Lanka. The novel appearance of DENV-3 in 1989 in Sri Lanka is considered to be responsible for the emergence of DHF in that year. [78] Similarly, in our study, DENV-4 was predominant in Pakistan, but DENV-2, DENV-3 and DENV-4 are known to have co-circulated in Pakistan from 2008 to 2011. These three serotypes share an Indian ancestry and are likely to have been introduced first into southern Pakistan. DENV-2 and DENV-3 had undergone in situ evolution to emerge as distinct, heterogeneous virus populations during the same period [79]. In the same way, all four strains were circulating in India, when a novel clade of DENV-4 (genotype I) abruptly emerged in Pune, India, during the 2016 season [80, 81].

Efforts to combat dengue infection by vaccinating susceptible and high-risk populations have been ongoing globally for over three decades, albeit without much success. Several candidate vaccines against dengue are in the pipeline [82, 83]. Since DENV-2 is known to be widely distributed across India, Nepal and Sri Lanka based on the studies included in our meta-analysis, the live attenuated CYD TDV tetravalent vaccine (Sanofi Pasteur, Lyon, France) that successfully met its targets in the phase III trial would also not be effective for SAARC countries [84] due to the resistance shown by DENV-2 to this vaccine [85, 86].

According to the WHO 2009 classification criteria, dengue cases are classified into dengue without warning signs, dengue with warning signs and severe dengue [87, 93]. However, due to the lack of data based on the WHO 2009 classification and evidence that has become available since the WHO 1997 classification, the severity of dengue has been classified into dengue fever, dengue hemorrhagic fever and dengue shock syndrome. This study showed that most dengue infection cases were less severe.

In our study, thrombocytopenia was present in nearly 50% of all dengue cases, primarily due to bone marrow suppression and increased peripheral destruction of platelets during the febrile and early convalescent phase of the disease [88]. This result is similar to that reported in a retrospective cohort study where the prevalence of thrombocytopenia among patients with confirmed dengue cases was 40.3% [89]. The rapid decline in platelet count indicates dengue with warning signs and helps the healthcare provider to classify the dengue infection. Thrombocytopenia is also a prognostic marker, and a platelet count < 20,000/ml blood is a good predictor of mortality in patients with severe dengue [90].

The results of our study lead us to conclude that the pooled dengue case fatality rate was 1.9% in SAARC countries [66]. This contrasts with a systematic review of dengue infection in India, where the pooled estimate of case fatality rate was 2.6% [80, 81]. The most likely reason for this difference is that in India all dengue strains responsible for multiple dengue outbreaks are circulating. The mortality in dengue cases is multifactorial, determined primarily by prior health status [91].

The WHO has set a target for dengue control by reducing the case fatality rate from 0.8% in 2020 to 0.0% in 2030 [92]. The WHO roadmap against neglected tropical diseases (NTDs) has prioritized a group of 20 NTDs, including dengue fever, that requires a global collaboration of all partners to achieve the target [92]. This dramatically emphasizes the need for an in-depth understanding of the epidemiology of dengue infection to combat it in SAARC countries.

Our systematic review has certain limitations. First, we included peer-reviewed literature from selected databases and excluded gray literature that provided additional data. Secondly, age was not uniformly reported in the included studies, and we did not estimate the prevalence of dengue cases by age. Third, we were not able to categorize the severity of dengue by the WHO 2009 classification since most of the included literature used data on the severity of dengue based on the WHO 1997 classification.

Conclusion

Dengue is common in South East Asian countries, with infected individuals showing a high seroprevalence of dengue IgG, IgM and both (IgM and IgG) antibodies and dengue NS1 antigen, in descending order or seroprevalence. DENV-2 was the most common strain, followed by DENV-1 and DENV-3; DENV-4 was the less reported strain. Fortunately, dengue fever was the most common presentation (80.5%), followed by DHF (18.2%) and dengue shock syndrome (1.5%). As the burden of dengue in the SAARC region is significant, the various governments and stakeholders need to focus on preventive measures, including vector control and timely diagnosis and treatment of the dengue cases.